Nine things we are asked to do
Engaged as an independent scientific consultancy by biotechnology sponsors, contract research organisations, diagnostics and ingredient developers, and academic spin-outs.
01Services
Where we are useful
The first six have pages of their own. The remaining three are usually scoped as part of a larger engagement rather than commissioned alone.
Genomic & multi-omic analysis
Bulk and single-cell RNA-seq, WGS and WES, amplicon and microarray data taken from raw files through to pathway-level conclusions and publication-grade figures.
Read moreStrain ID & GRAS safety
Whole-genome taxonomic identification to strain level, genome characterisation, and systematic screening for resistance determinants, virulence factors and toxigenic potential.
Read morePreclinical programmes
Model selection, endpoint definition, power and sample-size rationale, protocol authorship, and independent review of what your vendors send back.
Read moreHistopathology & imaging
IHC and immunofluorescence assay development on FFPE and frozen sections, confocal imaging, whole-slide scanning, QuPath quantification and scoring strategy.
Read moreBiomarker & IVD strategy
Moving a discovery-stage signature toward an assay a clinical or diagnostic programme can actually use, with the regulatory pathway in view from the start.
Read moreOrganoid & ex vivo models
Organoids established from primary surgical and biopsy tissue under IRB approval, tumoroid systems, and ex vivo orthotopic models for patient-specific compound testing.
Read moreImmunophenotyping & cell therapy characterisation
12+ colour flow cytometry panel design, compensation, gating strategy and FlowJo analysis, including characterisation of genetically modified T-cell products.
Scientific & regulatory writing
IND-enabling nonclinical summaries, study protocols and reports, GRAS safety narratives, IACUC and IRB submissions, manuscripts and SBIR/STTR proposals.
CRO selection & sponsor-side oversight
Independent technical review of vendor deliverables so problems surface before they become expensive. No instruments of our own, so no stake in the answer.
02Indications
Where the experience is deep
Fifteen years concentrated in rare pulmonary, neonatal, cardiovascular and oncology disease, with microbial safety work drawing on a microbiology background.
- Pulmonary & vascular
- Pulmonary arterial hypertension, hypoxic pulmonary hypertension, pulmonary fibrosis, bronchopulmonary dysplasia, congenital diaphragmatic hernia
- Neonatal & perinatal
- Necrotising enterocolitis, neonatal hypoxic-ischaemic brain injury, intra-amniotic inflammation, fetal systemic inflammatory response
- Cardiovascular
- Sickle cell cardiomyopathy and ventricular arrhythmia, myocardial infarction imaging, diastolic dysfunction genomics
- Neurology
- Peripheral nerve injury and Schwann cell repair, allopregnanolone neuroprotection in hypoxic-ischaemic injury, genomic profiling in undiagnosed rare neurological disease
- Microbial & food safety
- Probiotic, starter culture and fermentation strains, taxonomic identification, resistance and virulence screening, GRAS safety assessment
- Oncology
- Breast (hormone-receptor positive, aromatase-inhibitor resistant), colorectal and FAP, pancreatic neuroendocrine, lung, gastric metaplasia; experimental carcinogenesis and drug repurposing
Get started
Not sure which of these you need?
Describe the problem rather than the service. Most engagements turn out to span two or three of these, and the scoping conversation is free.